Kinegic Proposal 150623 v1

Changed with the DEMO VERSION of CAD-KAS PDF-Editor (http://www.cadkas.com).
This text only appears in the demo version. This text can be removed with the full version.
ABOUT COMPANY
Brief Profile:
Kinegic Pharmaceuticals Pvt Ltd, a new technological driven and integrated pharmaceutical
company with in-depth domain expertise in the field of healthcare, has strong capabilities across the
spectrum of the pharmaceutical value chain. From New dosage forms to API supplies to 3rd party
contract manufacturing, we provide complete and comprehensive healthcare solutions. Company
implemented ISO9001:2015 quality management system and achieved certification from
international accreditation bodies. All associate manufacturing plants are approved by USFDA, DCGA,
cGMP, WHOGMP, TGA, EDQM, HACCP agencies.
Kinegic is specially focused on the development & commercialization of prescription medicines for the
treatment of various types of diseases & various therapeutic segments. Company developed new Drug
Delivery Systems (DDS's) such as Softgel, ODF, Gummies, Hard Gelatin Capsules, and Effervescent &
Nutraceuticals and launched 7 premium brands for 1st time in India. Company is based at Hyderabad,
India, currently operates in Nine states. Company innovative medicines/brands are prescribed by top
most doctors and are widely accepted by patients.
Kinegic closely associated with various leading USFDA Approved OEMs and signed the CMA for bulk
drugs, intermediates and impurities. Kinegic also focused on Oncology & Radiology API’s and Bulk
Drugs. The business model of Kinegic is to procure orders from large pharmaceutical companies and
This text only produce
appearsthe in the demoonversion.
products ContractThis text can beforremoved
manufacturing supplies.with theof
Details fullProducts:
version.Iopromide,
Gemcitabine, Iohexol, Ifosfamide, Cyclophosphamide etc.,
Kinegic offers a comprehensive range of services starting from formulation development to market
launch.
Our Services includes:

 Contract Research & Manufacturing Services(CRAMS)
 Formulations & Development of Novel Drug Delivery Systems
 Loan License
 New formulations with DCGI Approvals
 Institutional Business
 Technology Transfer
 Joint Ventures and Technical Collaborations
Revenue Business Verticals:

 Contract Manufacturing (For Large Corporates)
 Formulations/DDS – Domestic & Exports
 API’s & Intermediates – Domestic & Exports
 CRO-Clinical research services to pharma, biotech and Life-Science Industries.
Company Name Kinegic Pharmaceuticals Private Limited

CIN U33119TG2020PTC140375
Date of Incorporation 21st May 2020
PAN AAICK0859L
Registered Office 1-8-67/LIG-42, TSIIC Colony, Kushaiguda,
ECIL, Hyderabad – 500062, TS.
Corporate/Operations Office 1-1-236/11, 2nd Floor, Srinivas Nagar, Kapra, Hyderabad –
500062, Telangana, India.
Directors Vijaya Kumar Yarapatni – (DIN - 06421070)
Sitalaxmi Yerapatni - (DIN-06421077)
Activity We are in the market with monopoly and novel drug delivery system for
some common molecules for first time in India like AZITHROMYCIN in Soft
gel form, PARACETAMOL in Soft gel form, Multivitamins in Candies/
Gummies form with excellent taste and flavor. Other dosage forms are
Nano shots, Hard gelatin capsules, Oral Disintegrating Films (ODF). .
Our major activities:
1. Manufacture & supply of finished formulations/ Ethical and
prescription based pharma products.
2. Supply of API’s/ intermediates to various key customers
3. 3rd party contract manufacturing
4. Co-development of new drug delivery systems/ Products
5. Contract manufacturing of APIs ( Anti-Cancer, Radiology and
Anesthesia)
Our Premium Brands & ZithroSoft (Softgel) , Ondakine–4 (ODF), Kinervo–OD Softgel , Para- S 650
Products
Changed with the DEMO VERSION of CAD-KAS Softgel, Etozeal-MR
PDF-EditorSoftgel, Cobriol Softgel, Kine-D3 Nano shots, Noxipro
(http://www.cadkas.com).
DSR, Neuvo-vit Gummies, Insense, KineFer,Cal H2O,KineTends,K2Cal-M,
Kinestat-MF, Mom’s Gift.
Our Current Presence Telangana, Andhra Pradesh, Rajasthan, UP, MadhyaPradesh
Our Team Strength Vice President -3, NSM:1, ZSM: 2, RBMs-3, ABMs: 9
Marketing Officers/Associates:75
Licenses All applicable statutory, Regulatory approvals, Trade Marks & legal
compliance obtained.
Our Customers Base & Leading 75 Stockiest available across India
Stockists Products are approved by various leading corporate hospitals and Super
Specialty /Consultant Doctors.
Our cManufacturing Locations Bhiwadi, Mohali, Baddi, Mumbai and Hyderabad
Our Group Companies Vindhya Pharma,
Associate Companies Vibgyor Drugs Pvt Ltd, Kemmintek Labs Pvt Ltd,
1. Formulations/ APIs plant/CM Plants/R&D facilities are proposed to
buy as an Asset/outright/acquisition and merger model.
Business Expansion:
2. Expansion and dedicated line for Anti Cancer, Radiology and
Anesthesia products in APIs and formulations segment
3. More thrust and focus on core infrastructure business
segment.
4. Commercialization of patented technologies and products
in domestic and Global market
5. Project based investment and execution along with JV
Partners
Company has spent lot of resources for R&D (New Drug Delivery,
Intelligent drug delivery and Oncology, Radiology and Anesthesia)
products and obtained all approvals in last two years. Company
established Dedicated marketing set up, Stockiest, distributors for
Company Status:
commercialization of the products. Kinegic Products are approved and
prescribed by various leading corporate hospitals and key consultant
doctors. Company has very good presence in Telangana Andhra
Pradesh and Rajasthan market and planning to expand PAN India by
March 2024.
Company has tied up with various leading technology Partners and
Joint Venture and CMA Contract Manufacturers for Both APIs and Formulations.
Company scheduled to launch its products across India in Phased

Manner and focused on institutional sales.
Changed with the DEMO VERSION of CAD-KASCompany signed the contract
PDF-Editor with MNC for identifying and engaging
(http://www.cadkas.com).
1000 associate partners across India.
Business Activities
Keeping the above expansion in view Company requires to ramp up its
product capacities to meet the market demand.
Company has planned to introduce another 250 products in near

future
Pharma Market Size

According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x
in the next decade. India’s domestic pharmaceutical market is estimated at US$ 42 billion in
2021 and likely to reach US$ 65 billion by 2024 and further expand to reach ~US$ 120-130
billion by 2030. The Indian biotechnology industry was valued at US$ 64 billion in 2019 and is
expected to reach US$ 150 billion by 2025. India’s drugs and pharmaceuticals exports stood
at US$ 24.44 billion in FY21.
Key Management Team:
Sl.No Name of the Key Executive Designation Total Years of
Experience
1 Y.Vijaya Kumar,BTech,MBA MD&CEO 27
2 Y.Seetha Lakshmi,Mcom Director 20
3 Dr.Anurag Srivastav,MBBS,MS,FRCS Chief Advisor 33
4 Dr.Giriraj Kulkarni Ph.D, M.Pharma Chief Advisor-For 27
5 Dr.P.Venkatesh, MBBS,Ph.D CRO 25

6 Mr.Ramakanth,CA, ICWA,CS CFO 30
7 Dr.Murali Krishna, MSC CQO and Regulatory 32
8 Mr.Ravi Kumar, MSC CMO- Formulations 27
and APIs
9 Mr.Bhanu, Mpharm-Ph.D CTO & Head R&D 22
10 Mr.Vinod Kumar, M.Tech, M.S IT Head 12
11 Mr.Prabhakar ,MBA Sales Head 25
This text onlyappears
12 in
the demo version. This text
Mr.Venugopal can beAccounts
removedHeadwith the 28
version. full
Companies Proposed Facilities Details:
Sl. Proposed Total Area Production Capacity Valuation in Proposed
N Facility Crores Budget for
o M&A
1 1A/c & Tablets: 50 40 Crores
Company-1 40000Sq 0.75Billion/Year
(Production covered area Capsules:
Facility- 0.5Billion/Year
Exports& Liquid Orals:
Domestic) 4500KL/year
2 Company – 2 2.5 AC R&D Lab with complete 60 30 Crores

R&D Facility 36000Sq pilot production
Feet
Covered
Area
3 Company – 3 3.6A/c 150KL 125 70 Crores
API R&D and 50000Sq.Ft
Production Facility Covered Area
4 Domestic Business - - 40 10 Crores

expansion and
Deployment of
team for Global
Marketing
Total Value: 275 150 Crores
Proposal:
1. Debt and Equity combination

2. Equity Investment
3. Any other best business model
Business model, investment mode and business plans will be explained during the physical meeting with the
Investors.
R&D Facility:

Kinegic Proposal 150623 v1

Uploaded by

Copyright:

Available Formats

You might also like

Kinegic Proposal 150623 v1

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Kinegic Proposal 150623 v1

Uploaded by

Copyright:

Available Formats

Changed with the DEMO VERSION of CAD-KAS PDF-Editor (http://www.cadkas.com).

Our Services includes:

Revenue Business Verticals:

Company Name Kinegic Pharmaceuticals Private Limited

Our Group Companies Vindhya Pharma,

Company scheduled to launch its products across India in Phased

Company has planned to introduce another 250 products in near

Pharma Market Size

5 Dr.P.Venkatesh, MBBS,Ph.D CRO 25

2 Company – 2 2.5 AC R&D Lab with complete 60 30 Crores

4 Domestic Business - - 40 10 Crores

1. Debt and Equity combination

You might also like